Stock Rating Upgrade
During the last several trading days the Value Trend Rating for Supernus Pharmaceuticals Inc (NASDAQ: SUPN) improved from D to C reflecting improving fundamentals and high Appreciation Potential.
Recent Price Action
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) stock rose modestly by 0.5% on 11/8/24. The stock closed at $36.60. Moreover, trading volume in this advance was unusually high at 151% of normal. The stock has been strong relative to the market over the last nine months and has risen 7.4% during the last week.
Current PriceTarget Research Rating
SUPN’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
Supernus Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Supernus Pharmaceuticals has a slightly negative Appreciation Score of 40 and a neutral Power Rating of 55, and the Low Neutral Value Trend Rating results.
Be the first to comment